<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04650984</url>
  </required_header>
  <id_info>
    <org_study_id>PH-L19TNFDOX2-03/16</org_study_id>
    <nct_id>NCT04650984</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma</brief_title>
  <acronym>FIBROSARC</acronym>
  <official_title>A Phase III Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philogen S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philogen S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is an open-label, randomized, controlled, two-arm multi-center study of the&#xD;
      efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in&#xD;
      advanced or metastatic soft-tissue sarcoma patients.&#xD;
&#xD;
      In the study, 102 patients will be randomized in a 1:1 ratio to receive doxorubicin treatment&#xD;
      (Arm 1) or L19TNF treatment in combination with doxorubicin (Arm 2).&#xD;
&#xD;
      The primary objective of the trial is to evaluate if L19TNF in combination with doxorubicin&#xD;
      (Arm 2) given for unresectable or metastatic soft tissue sarcoma improves efficacy measured&#xD;
      as progression free survival, as compared to doxorubicin alone (Arm 1).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III, open label, randomized, controlled study in subjects with advanced or metastatic&#xD;
      soft tissue sarcoma. In the study, 102 patients will be enrolled and parallel assigned in a&#xD;
      1:1 fashion to one of two different arms, as follows:&#xD;
&#xD;
        -  ARM 1: Patients will receive 75 mg/m2 doxorubicin once every 3 weeks (reference&#xD;
           treatment).&#xD;
&#xD;
        -  ARM 2: Patients will receive 13 µg/kg L19TNF on days 1, 3 and 5 every 3 weeks in&#xD;
           combination with 60 mg/m2 doxorubicin (once every 3 weeks).&#xD;
&#xD;
      Anti-cancer activity will be assessed every 6 weeks during therapy and every 12 weeks&#xD;
      thereafter. Median PFS, PFS rates at 3, 6, 9, 12 and 18 months, mOS, OS rate at 12 and 18&#xD;
      months and ORR will be calculated.&#xD;
&#xD;
      Safety assessment will be performed on an ongoing basis during study participation, including&#xD;
      standard laboratory assessments. The incidence of AEs will be summarized by severity in all&#xD;
      patients with at least one study drug intake.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Progression free survival (mPFS)</measure>
    <time_frame>From randomization up to week 72</time_frame>
    <description>Progression-free survival PFS in a time-to-event analysis in the L19TNF plus Doxorubicin control group (Arm 2) versus the Doxorubicin alone treatment group (Arm 1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS rate</measure>
    <time_frame>At 3, 6, 9, 12, 18 months after randomization</time_frame>
    <description>Progression Free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>At 3, 6, 9, 12, 18 months after randomization</time_frame>
    <description>Rate of Complete Response and Partial Response of L19TNF plus Doxorubicin treatment group (Arm 2) versus Doxorubicin alone (Arm 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>At 12 months and 18 months after randomization</time_frame>
    <description>OS in the L19TNF plus Doxorubicin treatment group (Arm 2) versus Doxorubicin alone (Arm 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall survival (mOS)</measure>
    <time_frame>At 12 months and 18 months after randomization</time_frame>
    <description>mOS in the L19TNF plus Doxorubicin treatment group (Arm 2) versus Doxorubicin alone (Arm 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>From week 1 up to week 72</time_frame>
    <description>Number of patients with adverse events (AEs) assessed on CTCAE v.4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAFA assessment</measure>
    <time_frame>At day 1 of week 1 and week 2; at day 1 from week 4 up to week 18, every 3 weeks; at week 22-23 (EoT); at week 23-24 (first follow-up visit)</time_frame>
    <description>Assessment of the formation of human anti-fusion protein antibodies (HAFA) against L19TNF (Arm 2).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 75 mg/m2 doxorubicin once every 3 weeks (reference treatment).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 13 µg/kg L19TNF on days 1, 3 and 5 every 3 weeks in combination with 60 mg/m2 doxorubicin (once every 3 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onfekafusp alfa</intervention_name>
    <description>Patients will receive a fixed dose of L19TNF in combination with a fixed dose of doxorubicin.</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>L19TNF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18-75 years.&#xD;
&#xD;
          2. Patients must have histological evidence of advanced unresectable and/or metastatic&#xD;
             high-grade soft tissue sarcoma (grade 2 - 3 according to the FNLCC grading system) not&#xD;
             amenable to curative treatment with surgery or radiotherapy. The following tumor types&#xD;
             are included:&#xD;
&#xD;
               -  Malignant fibrous histiocytoma&#xD;
&#xD;
               -  Myxoid and round cell liposarcoma, pleomorphic liposarcoma or dedifferentiated&#xD;
&#xD;
               -  Liposarcoma&#xD;
&#xD;
               -  Pleomorphic rhabdomyosarcoma&#xD;
&#xD;
               -  Myxofibrosarcoma intermediate and high-grade&#xD;
&#xD;
               -  Fibrosarcoma&#xD;
&#xD;
               -  Leiomyosarcoma&#xD;
&#xD;
               -  Angiosarcoma&#xD;
&#xD;
               -  Alveolar rhabdomyosarcoma&#xD;
&#xD;
               -  Unclassified sarcoma NOS&#xD;
&#xD;
             The following tumor types will not be included:&#xD;
&#xD;
               -  GIST&#xD;
&#xD;
               -  Mixed mesodermal tumor&#xD;
&#xD;
               -  Chondrosarcoma&#xD;
&#xD;
               -  Synovial sarcoma&#xD;
&#xD;
               -  Malignant peripheral nerve sheath tumor&#xD;
&#xD;
               -  Epithelioid sarcoma&#xD;
&#xD;
               -  Embryonal rhabdomyosarcoma&#xD;
&#xD;
               -  Malignant mesothelioma&#xD;
&#xD;
               -  Neuroblastoma&#xD;
&#xD;
               -  Osteosarcoma&#xD;
&#xD;
               -  Ewing's sarcoma / primitive neuroectodermal tumor&#xD;
&#xD;
               -  Desmoplastic small round cell tumor&#xD;
&#xD;
               -  Alveolar soft part sarcoma&#xD;
&#xD;
          3. Patients must have at least one unidimensionally measurable lesion by computed&#xD;
             tomography as defined by RECIST criteria 1.1. This lesion should not have been&#xD;
             irradiated during previous treatments.&#xD;
&#xD;
          4. Life expectancy of at least 3 months.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.&#xD;
&#xD;
          6. Documented negative test for HIV-HBV-HCV. For HBV serology: the determination of&#xD;
             HBsAg, anti-HBsAg-Ab and anti-HBCAg-Ab is required. In patients with serology&#xD;
             documenting previous exposure to HBV (i.e., anti-HBs Ab with no history of vaccination&#xD;
             and/or anti-HBc Ab), negative serum HBV-DNA is required. For HCV: HCV-RNA or HCV&#xD;
             antibody test. Subjects with a positive test for HCV antibody but no detection of&#xD;
             HCV-RNA indicating no current infection are eligible.&#xD;
&#xD;
          7. Negative serum pregnancy test for females of childbearing potential* within 14 days of&#xD;
             starting treatment.&#xD;
&#xD;
          8. Informed consent signed and dated to participate in the study.&#xD;
&#xD;
          9. Willingness and ability to comply with the scheduled visits, treatment plan,&#xD;
             laboratory tests and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior therapy (except surgery and radiation) for unresectable or metastatic malignant&#xD;
             soft tissue sarcoma.&#xD;
&#xD;
          2. Previous treatment with anthracycline-containing chemotherapy.&#xD;
&#xD;
          3. Radiotherapy within 4 weeks prior to therapy.&#xD;
&#xD;
          4. Known history of allergy to TNFα, anthracyclines or other intravenously administered&#xD;
             human proteins/peptides/antibodies.&#xD;
&#xD;
          5. Absolute neutrophil count (ANC) &lt; 1.5 x 109/L, platelets &lt; 100 x 109/L and haemoglobin&#xD;
             (Hb) &lt; 9.0 g/dl.&#xD;
&#xD;
          6. Chronically impaired renal function or creatinine ≥ 2.0 x ULN.&#xD;
&#xD;
          7. Inadequate liver function (ALT, AST, ALP or total bilirubin ≥ 2.5 x ULN.&#xD;
&#xD;
          8. Any severe concomitant condition which makes it undesirable for the patient to&#xD;
             participate in the study or which could jeopardize compliance with the protocol.&#xD;
&#xD;
          9. History within the last year of acute or subacute coronary syndromes including&#xD;
             myocardial infarction, unstable or severe stable angina pectoris.&#xD;
&#xD;
         10. Heart insufficiency (&gt; Grade II, New York Heart Association (NYHA) criteria).&#xD;
&#xD;
         11. Clinically significant cardiac arrhythmias or requiring permanent medication.&#xD;
&#xD;
         12. Uncontrolled hypertension, despite optimal therapy.&#xD;
&#xD;
         13. Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche-Fontaine&#xD;
             classification).&#xD;
&#xD;
         14. Severe diabetic retinopathy such as severe non-proliferative retinopathy and&#xD;
             proliferative retinopathy.&#xD;
&#xD;
         15. Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery)&#xD;
             within 4 weeks of administration of study treatment.&#xD;
&#xD;
         16. Pregnancy or breast-feeding.&#xD;
&#xD;
         17. Requirement of chronic administration of corticosteroids or other immunosuppressant&#xD;
             drugs. Limited use of corticosteroids to treat or prevent acute hypersensitivity&#xD;
             reactions is not considered an exclusion criterion.&#xD;
&#xD;
         18. Presence of active and uncontrolled infections or other severe concurrent disease,&#xD;
             which, in the opinion of the investigator, would place the patient at undue risk or&#xD;
             interfere with the study.&#xD;
&#xD;
         19. Known active or latent tuberculosis (TB).&#xD;
&#xD;
         20. Concurrent malignancies other than Soft Tissue Sarcoma, unless the patient has been&#xD;
             disease-free for at least 2 years.&#xD;
&#xD;
         21. Growth factors or immunomodulatory agents within 7 days prior to the administration of&#xD;
             study treatment.&#xD;
&#xD;
         22. Serious, non-healing wound, ulcer or bone fracture.&#xD;
&#xD;
         23. Allergy to study medication or excipients in study medication.&#xD;
&#xD;
         24. Concurrent therapy with anticoagulants.&#xD;
&#xD;
         25. Concurrent use of other anti-cancer treatments or agents other than study medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Teresa Hemmerle, PhD</last_name>
    <phone>+39 0577 17816</phone>
    <email>regulatory@philogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Serena Bettarini, Pharmacist</last_name>
    <email>regulatory@philogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helios Klinikum Bad Saarow</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Pink, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Muenster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Schliemann, Prof. MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>November 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

